bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 4 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Table 4: Combination Index (CI) Values. CI values calculated using the Chou and Talalay method from SRB proliferation data for varying concentrations of Nutlin and MLN8237 in combination. CI < 1 indicates synergy; CI = 1 additivity; CI > 1 antagonism
Supplementary Table 2 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Table 2: Sensitivity of CAL-51 KD clones to MLN8237 in vitro.
Supplementary Table 2 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Table 2: List of gene probes with specific sensitivity on a category of mutation and lineage combination
Supplementary Table 1 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Table 1: Sensitivity of TNBC cell lines to MLN8237 in vitro. IC50 values were calculated from the SRB proliferation curves.
Supplementary Figure 2 from Integrated Analysis of Transcriptomes of Cancer Cell Lines and Patient Samples Reveals STK11/LKB1–Driven Regulation of cAMP Phosphodiesterase-4D
Authors: He Ningning , Kim Nayoung , Song Mee , Park Choa , Kim Somin , Park Eun Young , Yim Hwa Young , Kim Kyunga , Park Jong Hoon , Kim Keun Il , Zhang Fan , Mills Gordon B. , Yoon Sukjoon
Published: April 2023

Supplementary Figure 2: Knockdown efficacy of siRNA treatment
Supplementary Figure 3 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Figure 3. Effects of MLN8237 on markers of apoptosis and senescence. A-B) Immunofluorescence analysis of p53 wildtype CAL-51 TNBC cell line stably transfected with a p73 shRNA construct (p73-55).
Supplementary Figure 2 from p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer
Authors: Tentler John J. , Ionkina Anastasia A. , Tan Aik Choon , Newton Timothy P. , Pitts Todd M. , Glogowska Magdalena J. , Kabos Peter , Sartorius Carol A. , Sullivan Kelly D. , Espinosa Joaquin M. , Eckhardt S. Gail , Diamond Jennifer R.
Published: April 2023

Supplementary Figure 2. Quantification of total cell counts and average cellular size at Day 15 as depicted in Fig. 4A.
Supplemental Figure Legend from Changes in BAI1 and Nestin Expression Are Prognostic Indicators for Survival and Metastases in Breast Cancer and Provide Opportunities for Dual Targeted Therapies
Authors: Meisen Walter Hans , Dubin Samuel , Sizemore Steven T. , Mathsyaraja Haritha , Thies Katie , Lehman Norman L. , Boyer Peter , Jaime-Ramirez Alena Cristina , Elder J. Bradley , Powell Kimerly , Chakravarti Arnab , Ostrowski Michael C. , Kaur Balveen
Published: April 2023

Supplemental Figure Legend
Supplementary Materials and Methods from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Materials and Methods. Quantification of mRNA Expression Immunohistochemistry (IHC)
Supplementary Figure 2 from Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Authors: Alewine Christine , Xiang Laiman , Yamori Takao , Niederfellner Gerhard , Bosslet Klaus , Pastan Ira
Published: April 2023

Supplementary Figure 2. Demonstrates no activity of a control non-binding immunotoxin in vitro and in vivo
Supplementary Fig. 7 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 7. p53-independent effects of AMG 232
Supplementary Figure 1 from Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor
Authors: Larsen Andrew R. , Bai Ren-Yuan , Chung Jon H. , Borodovsky Alexandra , Rudin Charles M. , Riggins Gregory J. , Bunz Fred
Published: April 2023

Supplementary Figure 1: (A) Survival of mice with DAOY-derived orthotopic tumors at 25 mg/kg MBZ (n=4) or mock-treated (n=3). One mouse from the mock treatment group did not develop symptoms of a growing brain tumor, and was euthanized after surviving for more than six months. This mouse was not found to have a brain tumor, and was therefore omitted from this analysis. (B) RNA was harvested from untreated and treated tumors and assessed by qRT-PCR for expression of GLI1, PTCH1, and PTCH2.
Supplementary Fig. 4 from Small Molecule Inhibition of MDM2–p53 Interaction Augments Radiation Response in Human Tumors
Authors: Werner Lauryn R. , Huang Shyhmin , Francis David M. , Armstrong Eric A. , Ma Fang , Li Chunrong , Iyer Gopal , Canon Jude , Harari Paul M.
Published: April 2023

Supplementary Fig. 4. (A) Induction of autophagy-related genes in SJSA-1 cells (B) Lack of significant induction of apoptosis
Supplemental table 1 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Table showing indication, specific PIK3CA and PTEN mutations, as well as ErbB2 amplification status.
Supplemental Figure 3 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Western blots and quantification of time course of HRG-stimulated signaling (pAKT-S473, pERK1/2) in NCI-N87, SKBR3, OVCAR8, and HCC1937 control cell lines.
Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Table 1. Characteristics of cell lines used in study
Supplemental Figure 2 from Heregulin–ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
Authors: Yarar Defne , Lahdenranta Johanna , Kubasek William , Nielsen Ulrik B. , MacBeath Gavin
Published: April 2023

Growth rates of control (GFP/EV) or PIK3CA- (WT or H1047R mutant) expressing NCI-N87, SKBR3, OVCAR8, and HCC1937 cells grown in 3D culture.
Supplemental Figure Legends from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Legends for supplemental figures
Supplementary Table S1 from Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Authors: Peng Zhi , Li Zhongwu , Gao Jing , Lu Ming , Gong Jifang , Tang En-Tzu , Oliner Kelly S. , Hei Yong-Jiang , Zhou Hui , Shen Lin
Published: April 2023

Overall Survival Comparison Between MET Subgroups by Treatment Disposition
Supplementary Figure S2 from Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression
Authors: Woo Jong Kyu , Kang Ju-Hee , Shin DongYun , Park Seong-Hyeok , Kang Kyungsu , Nho Chu Won , Seong Je Kyung , Lee Sang-Jin , Oh Seung Hyun
Published: April 2023

Supplementary Figure S2. Daurinol increase the cell cycle abnormalities
Supplementary tables from Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer
Authors: Hunter Francis W. , Hsu Huai-Ling , Su Jiechuang , Pullen Susan M. , Wilson William R. , Wang Jingli
Published: April 2023

Supplementary Tables. Supplementary Tables (including statistical analysis of relationships between one-electron reductase activity, HR status and chemosensitivity) and supplementary references related to this material
Supplementary Figures S1-S5 from Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations
Authors: Bonelli Mara A. , Cavazzoni Andrea , Saccani Francesca , Alfieri Roberta R. , Quaini Federico , La Monica Silvia , Galetti Maricla , Cretella Daniele , Caffarra Cristina , Madeddu Denise , Frati Caterina , Lagrasta Costanza Annamaria , Falco Angela , Rossetti Pietro , Fumarola Claudia , Tiseo Marcello , Petronini Pier Giorgio , Ardizzoni Andrea
Published: April 2023

Supplementary Figures S1-S5. Figure S1: p-AKT levels in PIK3CA transfected clones Figure S2: Induction of cell death after treatment with PI3K inhibitors Figure S3: Time course evaluation of PI3K/AKT/mTOR pathway activity after exposure to PI3K inhibitors Figure S4: Evaluation of cell migration after treatment with PI3K inhibitors Figure S5: CD133 expression in tumor spheres
Supplementary Figure 6 from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure 6: Steroidogenesis gene expression from pharmacodynamic study.
Supplementary Figure 5 from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure 5: Additional details of in vivo study.
Supplementary Figure 3 from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure 3: Supplementary results on SRBEP-1 and HMGCR transcripts.
Supplementary Tables 1 - 5 and Figures 1 - 3 from Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
Authors: Dokter Wim , Ubink Ruud , van der Lee Miranda , van der Vleuten Monique , van Achterberg Tanja , Jacobs Danielle , Loosveld Eline , van den Dobbelsteen Diels , Egging David , Mattaar Ellen , Groothuis Patrick , Beusker Patrick , Coumans Ruud , Elgersma Ronald , Menge Wiro , Joosten John , Spijker Henri , Huijbregts Tijl , de Groot Vincent , Eppink Michel , de Roo Guy , Verheijden Gijs , Timmers Marco
Published: April 2023

Supplementary tables describe a comparison of half-lives of SYD983 in the different species (Table S1), PK details in mice (Table S2), PK details in tumor-bearing mice (Table S3), PK details in cynomolgus monkeys (Tables S4 and S5), Flow rates of SYD983 in RP-HPLC, HIC profile of SYD983 and SYD985 (Figure S1), Cytotoxicity of SYD983 versus SYD985 (Figure S2), and control staining for IHC of the tumors used in PDX (Figure S3).
Supplementary Table 2 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Table 2: Biochemical activity of WT and A687V EZH2 complexes with modified histone peptides
Supplementary Figure 7 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 7: Comparison of the active sites and residue numbering of multiple related lysine methyltransferases
Supplementary Figure 4 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Figure 4: Gamma-secretase inhibition did not impair MIA PaCa-2 cell migration.
Supplementary Figure 2 from The NOTCH Ligand JAGGED2 Promotes Pancreatic Cancer Metastasis Independent of NOTCH Signaling Activation
Authors: Hu Yufeng , Su Hexiu , Li Xu , Guo Guoli , Cheng Ling , Qin Renyi , Qing Guoliang , Liu Hudan
Published: April 2023

Supplementary Figure 2: Jagged2-depleted MIA PaCa-2 cells exhibited metastatic defects.
Supplementary Figure 3 from A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation
Authors: Ott Heidi M. , Graves Alan P. , Pappalardi Melissa B. , Huddleston Michael , Halsey Wendy S. , Hughes Ashley M. , Groy Arthur , Dul Edward , Jiang Yong , Bai Yuchen , Annan Roland , Verma Sharad K. , Knight Steven D. , Kruger Ryan G. , Dhanak Dashyant , Schwartz Benjamin , Tummino Peter J. , Creasy Caretha L. , McCabe Michael T.
Published: April 2023

Supplementary Figure 3: Biochemical activity of PRC2 complexes containing WT, A687V, Y641N, or A677G EZH2 using a library of histone H3 peptides containing H3K27
Supplementary Materials and Methods from Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
Authors: Pal Krishnendu , Pletnev Alexandre A. , Dutta Shamit K. , Wang Enfeng , Zhao Ruizhi , Baral Aradhita , Yadav Vinod Kumar , Aggarwal Suruchi , Krishnaswamy Soundararajan , Alkharfy Khalid M. , Chowdhury Shantanu , Spaller Mark R. , Mukhopadhyay Debabrata
Published: April 2023

Detailed procedure for the synthesis of lipidated peptides.
Supplementary Figure 2 from Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
Authors: Pal Krishnendu , Pletnev Alexandre A. , Dutta Shamit K. , Wang Enfeng , Zhao Ruizhi , Baral Aradhita , Yadav Vinod Kumar , Aggarwal Suruchi , Krishnaswamy Soundararajan , Alkharfy Khalid M. , Chowdhury Shantanu , Spaller Mark R. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Figure 2: CD31 and HandE staining of tumor tissue sections obtained from AP1063-treated and AP1032-treated groups.
Supplementary Figure 1 from Inhibition of Endoglin–GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
Authors: Pal Krishnendu , Pletnev Alexandre A. , Dutta Shamit K. , Wang Enfeng , Zhao Ruizhi , Baral Aradhita , Yadav Vinod Kumar , Aggarwal Suruchi , Krishnaswamy Soundararajan , Alkharfy Khalid M. , Chowdhury Shantanu , Spaller Mark R. , Mukhopadhyay Debabrata
Published: April 2023

Supplementary Figure 1: CD31 and HandE staining of tumor tissue sections obtained from control and Endoglin shRNA treated cells.
Supplemental Figure 9 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 9. Representative bioluminescence image (left) and visible lung metastasis (right) from NSG mice inoculated with 231/Luc cells (control group)
Supplemental Figure 7 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 7. Effect of ENT treatment on formation of tumors and lung metastasis in NSG mice
Data Supplement from Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α
Authors: Rossi Edmund A. , Rossi Diane L. , Cardillo Thomas M. , Chang Chien-Hsing , Goldenberg David M.
Published: April 2023

Additional flow cytometry data for trogocytosis. Figure S5 shows viability of T cells and BxPC3 target cells. Figure S6 shows formation of immunological synapses and transfer of CD4 from T cells to target cells.
Supplementary Figures S1-S6 from Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
Authors: Barton Valerie N. , D'Amato Nicholas C. , Gordon Michael A. , Lind Hanne T. , Spoelstra Nicole S. , Babbs Beatrice L. , Heinz Richard E. , Elias Anthony , Jedlicka Paul , Jacobsen Britta M. , Richer Jennifer K.
Published: April 2023

Supplementary Figure S1-Full length western blots and enzalutamide treatment of SUM159PT-ARF876L Supplementary Figure S2-Xenograft caliper measurements and total flux at randomization. Supplementary Figure S3-Xenograft caliper measurements and tumor weights. Supplementary Figure S4-HCC1806 xenografts treated with enzalutamide. Supplementary Figure S5- Changes in proliferation and apoptosis during scratch wound assay. Supplementary Figure S6-Signaling, proliferation, and invasion of SUM159PT shAR15 cells treated with amphiregulin.
Supplemental Figure 3 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 3. Effect of ENT on mammosphere formation
Supplemental Figure Legends from Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
Authors: Barton Valerie N. , D'Amato Nicholas C. , Gordon Michael A. , Lind Hanne T. , Spoelstra Nicole S. , Babbs Beatrice L. , Heinz Richard E. , Elias Anthony , Jedlicka Paul , Jacobsen Britta M. , Richer Jennifer K.
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 2 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 2. Effect of ENT on Hoescht dye exclusion
Supplemental Figure 1 from Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells
Authors: Schech Amanda , Kazi Armina , Yu Stephen , Shah Preeti , Sabnis Gauri
Published: April 2023

Supplemental Figure 1. Effect of ENT treatment on CD44 using IF
Supplementary Figure S9 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S9: Semi-quantitative analyses of the Western blot result of HCT116 cells in Fig. 5E
Supplemental Table S1 from Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts
Authors: Kyle Alastair H. , Baker Jennifer H.E. , Gandolfo Maria-Jose , Reinsberg Stefan A. , Minchinton Andrew I.
Published: April 2023

Supplemental Table S1 - Comparison of plasma half-life in mice, active metabolite and partitioning of the camptothecin analogues used in this study.
Supplemental Figures S1 & S2 from Tissue Penetration and Activity of Camptothecins in Solid Tumor Xenografts
Authors: Kyle Alastair H. , Baker Jennifer H.E. , Gandolfo Maria-Jose , Reinsberg Stefan A. , Minchinton Andrew I.
Published: April 2023

Supplemental FIGS S1 & S2 - Whole tissue section images comparing drug extravasation in HCT116 and HT29 xenografts.
Supplementary Figure S7 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S7: Semi-quantitative analyses of the Western blot result in Fig. 3C
Supplementary Figure S5 from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure S5: Semi-quantitative analyses of the Western blot result of HCT116 cells treated with OSI-906 in Fig. 3B
Supplementary Table S2 from miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer
Authors: Tang Hailin , Liu Peng , Yang Lu , Xie Xinhua , Ye Feng , Wu Minqing , Liu Xiaoping , Chen Bo , Zhang Lijuan , Xie Xiaoming
Published: April 2023

Univariate and multivariable Cox regression analysis of DFS (Cox proportional hazards regression model)
Supplementary Table S1 from miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer
Authors: Tang Hailin , Liu Peng , Yang Lu , Xie Xinhua , Ye Feng , Wu Minqing , Liu Xiaoping , Chen Bo , Zhang Lijuan , Xie Xiaoming
Published: April 2023

Univariate and multivariable Cox regression analysis of OS (Cox proportional hazards regression model)
Supplementary Figure 3 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

Supplementary Figure 3: Effects of RTA 408 on prostate cancer cell survival in vitro. Cells were treated for 24 h with RTA 408 at different concentrations. Protein extracts were prepared from attached and/or detached cells to capture the full extent of apoptosis. Protein extracts from detached cells were prepared at RTA 408 concentrations {greater than or equal to}0.5 μM; solid lines above protein concentrations indicate detached cells as a source of proteins. Levels of cleaved caspase 3, cleaved PARP-1, cleaved cytokeratin-18 (M30) and cleaved caspase-8 were determined by immunoblot analyses.
Supplementary Figure Legend from Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells
Authors: Zhang Yan , Wang Qing , Chen Li , Yang Hsin-Sheng
Published: April 2023

Supplementary Figure Legend
Supplementary Figure 1 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich
Published: April 2023

Supplementary Figure 1: Reduction in apoptosis incidence in the skin of irradiated mice. Topical radiation (30 Gy single dose) was applied to the hindlegs of mice with shielding protecting the rest of the body. RTA 408 (17.5 mg/kg) was administered 1 d prior, 1 h prior and 1 d post IR; skins were harvested 2 d post IR. Apoptotic cells were detected by TUNEL staining in tissue samples obtained 24 h after radiation exposure. The number of apoptotic cells in RTA 408-treated mice was statistically significantly reduced compared to IR + vehicle-treated mice (Student's t-test; p<0.05). DP = dermal papilla; hf = hair follicle; e = epidermis; d = dermis; m{plus minus}SD of at least six fields were evaluated.
Supplementary Figure Legends from Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models
Authors: Hu Chaoxin , Dadon Tikva , Chenna Venugopal , Yabuuchi Shinichi , Bannerji Rajat , Booher Robert , Strack Peter , Azad Nilofer , Nelkin Barry D. , Maitra Anirban
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 6 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

Local mice xenograft tumor radiation settings showing the images of xenograft tumors derived from HCT116 cells harboring Thr150/Ser159 mutant or wild type SIRT3
Supplementary Figure 4 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

MnSOD activity in MCF10A cells harboring mock, wild type or Thr150/Ser159 mutant SIRT3 following irradiation
Supplementary figure legends from Silencing Egr1 Attenuates Radiation-Induced Apoptosis in Normal Tissues while Killing Cancer Cells and Delaying Tumor Growth
Authors: Zhao Diana Yi , Jacobs Keith M. , Hallahan Dennis E. , Thotala Dinesh
Published: April 2023

Figure legends for supplementary figures
Supplementary Figure 3 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

Western blot of mitochondrial acetylated proteins from irradiated MDA-231 or U87 cells harboring wild-type or Thr150/Ser159 mutant SIRT3.
Supplementary Figure 2 from Silencing Egr1 Attenuates Radiation-Induced Apoptosis in Normal Tissues while Killing Cancer Cells and Delaying Tumor Growth
Authors: Zhao Diana Yi , Jacobs Keith M. , Hallahan Dennis E. , Thotala Dinesh
Published: April 2023

Knocking down Egr1 in normal cell lines reduces degree of apoptotic morphology after irradiation.
Supplementary Figure 2 from CDK1-Mediated SIRT3 Activation Enhances Mitochondrial Function and Tumor Radioresistance
Authors: Liu Rui , Fan Ming , Candas Demet , Qin Lili , Zhang Xiaodi , Eldridge Angela , Zou June X. , Zhang Tieqiao , Juma Shuaib , Jin Cuihong , Li Robert F. , Perks Julian , Sun Lun-Quan , Vaughan Andrew T.M. , Hai Chun-Xu , Gius David R. , Li Jian Jian
Published: April 2023

The potential phosphorylation motifs of human SIRT3 were predicted by searching the data base using the combination of software Netphos2.0 server and Automotif server
Supplementary Figure 1 from Silencing Egr1 Attenuates Radiation-Induced Apoptosis in Normal Tissues while Killing Cancer Cells and Delaying Tumor Growth
Authors: Zhao Diana Yi , Jacobs Keith M. , Hallahan Dennis E. , Thotala Dinesh
Published: April 2023

Radioprotection in Egr1 knockout mice was also observed at an earlier time point.
Table S2 from AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray
Authors: Alhakamy Nabil A. , Ishiguro Susumu , Uppalapati Deepthi , Berkland Cory J. , Tamura Masaaki
Published: April 2023

Table S2. Number of tumor nodules in LLC tumor-bearing mice
Supplementary Table S4 from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Authors: Wheler Jennifer J. , Janku Filip , Naing Aung , Li Yali , Stephen Bettzy , Zinner Ralph , Subbiah Vivek , Fu Siqing , Karp Daniel , Falchook Gerald S. , Tsimberidou Apostolia M. , Piha-Paul Sarina , Anderson Roosevelt , Ke Danxia , Miller Vincent , Yelensky Roman , Lee J. Jack , Hong David , Kurzrock Razelle
Published: April 2023

Next generation sequencing gene list (Foundation Medicine) (N = 236 genes a)
Supplementary Table S3 from TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics
Authors: Wheler Jennifer J. , Janku Filip , Naing Aung , Li Yali , Stephen Bettzy , Zinner Ralph , Subbiah Vivek , Fu Siqing , Karp Daniel , Falchook Gerald S. , Tsimberidou Apostolia M. , Piha-Paul Sarina , Anderson Roosevelt , Ke Danxia , Miller Vincent , Yelensky Roman , Lee J. Jack , Hong David , Kurzrock Razelle
Published: April 2023

Tumor types in the study
Figure S2 from AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray
Authors: Alhakamy Nabil A. , Ishiguro Susumu , Uppalapati Deepthi , Berkland Cory J. , Tamura Masaaki
Published: April 2023

Figure S2. Bar graphs show average lung weight (A) and number of lung tumor nodules (B) in LLC tumor-bearing C57BL/6 mice treated with PBS (n=5), K9-pLUC-Ca2+ IV (K9-pLUC IV; n=5), or K9-pLUC-Ca2+ IT (K9-pLUC IT; n=4). K9, nine amino acid polylysine; IT, intratracheal; IV, intravenous.
Supplementary Figure S2 from MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model
Authors: Bartholomeusz Chandra , Xie Xuemei , Pitner Mary Kathryn , Kondo Kimie , Dadbin Ali , Lee Jangsoon , Saso Hitomi , Smith Paul D. , Dalby Kevin N. , Ueno Naoto T.
Published: April 2023

MDA-MB-231 cells were transfected with siMEK1/2 or scrambled control siRNA. 48 hours after transfection cells were plated in 3D culture and treated with selumetinib for 48 hours. For western blot analysis, cell pellets were lysed as described previously with ÃŽÂ²-actin used as a loading control (16). Primary antibodies were anti-phospho-p42/44 MAPK (Thr202/Tyr204) (1:1000 dilution; Cell Signaling), anti-ÃŽÂ²-actin (1:5000 dilution; Sigma-Aldrich), anti-fibronectin (1:500 dilution; BD Transduction), anti-vimentin (1:1000 dilution; Cell Signaling), anti-E-cadherin (1:1000 dilution; BD Transduction), anti-beta-catenin (1:1000 dilution; Cell Signaling). Secondary antibodies were horseradish peroxidase-conjugated IgG (1:10,000 dilution; Invitrogen) for chemiluminescent signal detection and the corresponding Alexa Fluor-conjugated IgG (1:5000 dilution; Invitrogen) for fluorescence signal detection.
Supplementary Table from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Authors: Singh Rajeeva , Setiady Yulius Y. , Ponte Jose , Kovtun Yelena V. , Lai Katharine C. , Hong E. Erica , Fishkin Nathan , Dong Ling , Jones Gregory E. , Coccia Jennifer A. , Lanieri Leanne , Veale Karen , Costoplus Juliet A. , Skaletskaya Anna , Gabriel Rabih , Salomon Paulin , Wu Rui , Qiu Qifeng , Erickson Hans K. , Lambert John M. , Chari Ravi V.J. , Widdison Wayne C.
Published: April 2023

Supplementary Table S1: Amounts of catabolites generated upon treatment of cancer cells with CX and SMCC ADCs.
Supplementary Figure S1 from MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model
Authors: Bartholomeusz Chandra , Xie Xuemei , Pitner Mary Kathryn , Kondo Kimie , Dadbin Ali , Lee Jangsoon , Saso Hitomi , Smith Paul D. , Dalby Kevin N. , Ueno Naoto T.
Published: April 2023

A. we treated a panel of breast cancer cells MDA-MB-468, SUM190, KPL-4, and MDA-IBC-3 with different concentrations of selumetinib and assessed cell viability by WST-1 assay 72 hours later. We observed that in MDA-MB-468, SUM190, KPL-4, and MDA-IBC-3 cells, the 50% inhibitory concentration (IC50) was above 20 Ã‚ÂµM. B. MDA-MB-231 and SUM149 cells were treated with selumetinib for 72 hours, and FACS analysis was performed to determine cell cycle distribution using propidium iodide.
Supplementary Methods from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Authors: Singh Rajeeva , Setiady Yulius Y. , Ponte Jose , Kovtun Yelena V. , Lai Katharine C. , Hong E. Erica , Fishkin Nathan , Dong Ling , Jones Gregory E. , Coccia Jennifer A. , Lanieri Leanne , Veale Karen , Costoplus Juliet A. , Skaletskaya Anna , Gabriel Rabih , Salomon Paulin , Wu Rui , Qiu Qifeng , Erickson Hans K. , Lambert John M. , Chari Ravi V.J. , Widdison Wayne C.
Published: April 2023

Supplementary Methods (S1-S3). Supplementary Method S1: Synthesis of di-, tri-, tetra-glycyl, and valine-citrulline-glycine peptide linkers and catabolites. Supplementary Method S2: Test of in vitro cytotoxicity, cell-cycle inhibition, and bystander cytotoxic activity of ADCs. Supplementary Method S3: Catabolism of [3H]-labeled and non-radiolabeled CX and SMCC ADCs by cancer cells.
Supplementary Figures 1 through 10 and Supplementary Table 1 from A TORC2–Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers
Authors: Amin Dhara N. , Ahuja Deepika , Yaswen Paul , Moasser Mark M.
Published: April 2023

This file contains supplementary figures including the western blots corresponding to the schematics of figures 2,3,4,5, as well as additional data sets referred to in the paper.
Supplementary Figures from A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells
Authors: Singh Rajeeva , Setiady Yulius Y. , Ponte Jose , Kovtun Yelena V. , Lai Katharine C. , Hong E. Erica , Fishkin Nathan , Dong Ling , Jones Gregory E. , Coccia Jennifer A. , Lanieri Leanne , Veale Karen , Costoplus Juliet A. , Skaletskaya Anna , Gabriel Rabih , Salomon Paulin , Wu Rui , Qiu Qifeng , Erickson Hans K. , Lambert John M. , Chari Ravi V.J. , Widdison Wayne C.
Published: April 2023

Supplementary Figures (S1-S4). Supplementary Figure S1: In vitro cytotoxic activities of tetraglycyl (Gly4), triglycyl (Gly3), diglycyl (Gly2), and valine-citrulline-glycine (VCG)-linked anti-EGFR ADCs and a triglycyl-linked non-binding antibody ADC in PC-9, Ca9-22, HSC-2, H1975, A-431, and OSC-19 cells (3-4 DAR ADCs). Supplementary Figure S2: In vitro cytotoxic activities of anti-EpCAM CX and SMCC ADCs toward a low EpCAM antigen-expressing cell line, RPMI 8226 (~50,000 EpCAM per cell). The CX ADCs tested included a conjugate with a typical payload number (3.9 maytansinoid molecules per antibody molecule; 3.9 DAR) and conjugates with high payload numbers (8 and 9.6 DAR). The SMCC ADC had a typical payload number (4.3 DAR). Supplementary Figure S3: Binding-competition ELISA of catabolites of CX ADC (DM-CX1 and DM-CX2) and SMCC ADC (lysine-SMCC-DM1): inhibition by catabolites toward binding of anti-maytansine antibody to immobilized BSA-maytansinoid conjugate. Supplementary Figure S4: Test of bystander cytotoxic activity of anti-EGFR-CX-DM1 or SPDB-DM4 conjugate in mixed culture of EGFR-positive (Ca9-22) and EGFR-negative (Ramos) cells.
Supplementary Tables S5 and S6 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Analysis of mouse tissues and exploratory toxicological assessment in rats revealed a favorable rodent safety profile for BI 882370.
Supplementary table 2 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Authors: Lim Yangmi , Yoo Jiho , Kim Min-Soo , Hur Minkyu , Lee Eun Hee , Hur Hyung-Suk , Lee Jae-Chul , Lee Shi-Nai , Park Tae Wook , Lee Kyuhyun , Chang Ki Hwan , Kim Kuglae , Kang YingJin , Hong Kwang-Won , Kim Se-Ho , Kim Yeon-Gil , Yoon Yeup , Nam Do-Hyun , Yang Heekyoung , Kim Dong Geon , Cho Hyun-Soo , Won Jonghwa
Published: April 2023

Supplementary Table 2. Comparison of the EGFR binding constants between GC1118 and cetuximab
Supplementary Tables S1 and S2 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Data and statistics from x-ray co-crystallization experiments with BI 882370 or dabrafenib with the BRAF kinase domain.
Supplementary table 1 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Authors: Lim Yangmi , Yoo Jiho , Kim Min-Soo , Hur Minkyu , Lee Eun Hee , Hur Hyung-Suk , Lee Jae-Chul , Lee Shi-Nai , Park Tae Wook , Lee Kyuhyun , Chang Ki Hwan , Kim Kuglae , Kang YingJin , Hong Kwang-Won , Kim Se-Ho , Kim Yeon-Gil , Yoon Yeup , Nam Do-Hyun , Yang Heekyoung , Kim Dong Geon , Cho Hyun-Soo , Won Jonghwa
Published: April 2023

Supplementary Table 1. X-ray data collection and refinement statistics.
Supplementary Table S4 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Differentially expressed genes in vemurafenib-resistant vs. control A375 tumors, obtained from the in vivo study shown in Fig. 4.
Supplementary method from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Authors: Lim Yangmi , Yoo Jiho , Kim Min-Soo , Hur Minkyu , Lee Eun Hee , Hur Hyung-Suk , Lee Jae-Chul , Lee Shi-Nai , Park Tae Wook , Lee Kyuhyun , Chang Ki Hwan , Kim Kuglae , Kang YingJin , Hong Kwang-Won , Kim Se-Ho , Kim Yeon-Gil , Yoon Yeup , Nam Do-Hyun , Yang Heekyoung , Kim Dong Geon , Cho Hyun-Soo , Won Jonghwa
Published: April 2023

Surface plasmon resonance (SPR)
Supplementary Table S3 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Overview of in vivo efficacy of BI 882370 and comparator compounds tested as single agents or in combination using melanoma and colorectal cancer xenograft mouse models.
Supplementary figure 2 from GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands
Authors: Lim Yangmi , Yoo Jiho , Kim Min-Soo , Hur Minkyu , Lee Eun Hee , Hur Hyung-Suk , Lee Jae-Chul , Lee Shi-Nai , Park Tae Wook , Lee Kyuhyun , Chang Ki Hwan , Kim Kuglae , Kang YingJin , Hong Kwang-Won , Kim Se-Ho , Kim Yeon-Gil , Yoon Yeup , Nam Do-Hyun , Yang Heekyoung , Kim Dong Geon , Cho Hyun-Soo , Won Jonghwa
Published: April 2023

Supplementary Figure 2. The EGFR-GC1118 interaction is not disrupted by excess amounts of high- or low-affinity EGFR ligands. The indicated colorectal cancer cell lines were pre-incubated with 0.1 ug/ml of cetuximab or GC1118 for 2 h prior to the addition of EGFR ligands for 10 min (EGF, HB-EGF, BTC, and TGF-ï�¡, 20~500 ng/ml; AREG and EREG, 40~1000 ng/ml). The blue and red lines indicate the relative % of cetuximab and GC1118, respectively, bound to EGFR in the presence of competing ligands compared with bound antibodies in the absence of blocking ligands. Antibody binding to EGFR was assessed by measuring the fluorescence intensity using flow cytometry. The results are expressed as the average{plus minus}SE of % maximal binding of the antibody of triplicate experiments.
Supplementary Figures S1 - S6 from A Novel RAF Kinase Inhibitor with DFG-Out–Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
Authors: Waizenegger Irene C. , Baum Anke , Steurer Steffen , Stadtmüller Heinz , Bader Gerd , Schaaf Otmar , Garin-Chesa Pilar , Schlattl Andreas , Schweifer Norbert , Haslinger Christian , Colbatzky Florian , Mousa Sien , Kalkuhl Arno , Kraut Norbert , Adolf Günther R.
Published: April 2023

Supplementary Figure S1 - Structure of the BRAF kinase domain with BI 882370 and a bound glucose molecule Supplementary Figure S2 - Drug wash-out experiment prolonged phospho-ERK reduction in A375 melanoma cells treated with BI 882370 vs comparator compound. Supplementary Figure S3 - Pharmacokinetic analysis of BI 882370, dabrafenib and vemurafenib in nude mice bearing subcutaneous A375 melanoma tumors show higher concentration of BI 882370 in tumor than plasma. Supplementary Figure S4 - In vivo pharmacodynamic response shown by phospho-ERK reduction in A375 tumors in nude mice treated once with BI 882370. Supplementary Figure S5 - Efficacy of BI 882370 and vemurafenib in COLO 205 colorectal cancer xenograft model. Supplementary Figure S6 - Efficacy of BI 882370 or vemurafenib as single agents or BI 882370 in combination with ErbB family kinase inhibitor afatinib in HT-29 colorectal cancer model.
Supplementary Data from Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Authors: Chae Young Kwang , Davis Andrew A. , Jain Sarika , Santa-Maria Cesar , Flaum Lisa , Beaubier Nike , Platanias Leonidas C. , Gradishar William , Giles Francis J. , Cristofanilli Massimo
Published: April 2023

Supplemental Table 1. Genes and rearrangements studied; Supplemental Table 2: Genes added over time to Guardant360 assay; Supplemental Table 3. Defining concordance and partial concordance for a particular gene; Supplemental Table 4. Concordance and partial concordance among only genes with genomic alterations in either assay; Supplemental Table 5. Sensitivity, specificity, and diagnostic accuracy across 5 genes, including variants of unknown significance (VUS)
Supplementary Table S1, S2, S3, S4 and Supplementary Figure legends from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

Supplementary Table S1: Statistics of data collection and processing of AuroraB/INCENP in complex with BI 847325; Supplementary Table S2: Statistics of data collection and processing of MEK1 in complex with BI 847325; Supplementary Table S3: Statistics of data collection and processing of AuroraB/INCENP in complex with BI 811283; Supplementary Table S4: Pharmacokinetic parameters of BI 847325 in mice and humans. Human data from Schöffski et al (31).
Supplementary Figure S3 from A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Authors: Feng Jia-Hua , Nakagawa-Goto Kyoko , Lee Kuo-Hsiung , Shyur Lie-Fen
Published: April 2023

Experimental design, body weight and organ index of A375-R and A2058 xenograft studies
Supplementary Figure S5: Efficacy of BI 847325 in the MIAPaCa-2 (KRASG12C) model of human pancreatic adenocarcinoma. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

BomTac:NMRI-Foxn1nu mice bearing human MIAPaCa-2 tumors were treated with vehicle, BI 847325 at 10 mg/kg daily p.o., AZD6244 at 25 mg/kg twice daily p.o., GSK 1120212 at 0.25 mg/kg twice daily p.o. Data is plotted as average tumor volume with standard error of the mean (SEM). Adjusted p values: BI 847325 vs AZD6244 p<0.0001(statistical significant difference); BI 847325 vs GSK 1120212 p<0.0001(statistical significant difference).
Supplementary Figure S2 from A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice
Authors: Feng Jia-Hua , Nakagawa-Goto Kyoko , Lee Kuo-Hsiung , Shyur Lie-Fen
Published: April 2023

DETD-35 has no effect on cell-cycle distribution but induces apoptosis of A375-R cells
Supplementary Figure S4: Western blot analysis of MAPK pathway inhibition by BI 847325 in KRAS-mutant cell lines. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

(A), MEK1 and phospho-MEK1/2; (B) ERK1/2 and phospho-ERK1/2.
Supplementary Figure S1: Chemical structure of the AK-B inhibitor BI 811283. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases
Authors: Sini Patrizia , Gürtler Ulrich , Zahn Stephan K. , Baumann Christoph , Rudolph Dorothea , Baumgartinger Rosa , Strauss Eva , Haslinger Christian , Tontsch-Grunt Ulrike , Waizenegger Irene C. , Solca Flavio , Bader Gerd , Zoephel Andreas , Treu Matthias , Reiser Ulrich , Garin-Chesa Pilar , Boehmelt Guido , Kraut Norbert , Quant Jens , Adolf Günther R.
Published: April 2023

Chemical structure of BI 811283: 2,3-diamino-pyrimidine